PathAI’s AISight® Dx IMS platform supports digital consult workflow capabilities through the AISight Consults workflow, helping institutions manage pathology consults, second opinions, and referrals more efficiently while moving beyond fragmented processes often dependent on glass slide shipment, manual coordination, and disconnected communication. By supporting digital case submission, review, collaboration, and reporting within a unified IMS experience, AISight Dx can help reduce turnaround time, lower shipping-related costs, and simplify coordination across sites.
For consulting institutions, AISight Dx provides a standardized and trackable way to manage incoming consult cases within the IMS. Cases can be organized in cross-site worklists and identified by referring clients, with AISight-based rules supporting pathologist assignment. Consulting teams can review cases and complete reports directly in AISight Dx, helping reduce manual effort while supporting the growth of subspecialty consult services without adding unnecessary operational burden.
For referring institutions, AISight Dx offers a digital path to submit consult cases through bulk ingestion or manual upload, without requiring full LIS integration from day one. By reducing the need to package and ship glass slides, the workflow can help lower costs, reduce transit risk, and support faster access to subspecialty expertise. Referring physicians can also access slides, reports, and notes, receive status notifications when cases are finalized, and participate in real-time Q&A through annotations and AISight Live.
With consult workflow capabilities supported within AISight Dx, organizations can manage digital consult workflows in the same IMS environment used for broader digital pathology operations, creating a more connected experience for both consulting and referring institutions.
To learn more about the AISight Consults workflow in AISight Dx, visit https://www.pathai.com/aisightdx-digital-pathology-solution/aisight-consults
To learn more about how AISight Dx can support your organization, contact digitaldx@pathai.com
*AISight® Dx is FDA-cleared for primary diagnosis in the US and CE-IVD-marked for primary diagnosis in the EEA, UK, and Switzerland.
About AISight Dx
AISight® Dx, is PathAI’s cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine.
About PathAI
PathAI is a leading provider of AI-powered pathology solutions that aim to improve the accuracy of histology assessment and accelerate drug development. PathAI's platform leverages advanced artificial intelligence to analyze and interpret pathology images, providing valuable insights to pathologists, researchers, and pharmaceutical companies. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com and follow us on LinkedIn.